Development of enterovirus 71 vaccines
| Autor: | Luan-Ying Chang, Min-Shi Lee |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
viruses Immunology medicine.disease_cause Virus DNA vaccination Drug Discovery Epidemiology Enterovirus Infections medicine Enterovirus 71 Animals Humans Pharmacology Clinical Trials as Topic biology business.industry Poliovirus Outbreak Viral Vaccines biology.organism_classification Virology Enterovirus A Human Clinical trial Vaccination Vaccines Inactivated Molecular Medicine business |
| Zdroj: | Expert Review of Vaccines. 9:149-156 |
| ISSN: | 1744-8395 1476-0584 |
| DOI: | 10.1586/erv.09.152 |
| Popis: | Enterovirus 71 (EV71) was first isolated in 1969 in California, USA. Several epidemic outbreaks with high mortality rates have occurred in European and Asian Countries (Bulgaria in 1975, Hungary in 1978, Malaysia in 1997, Taiwan in 1998 and China in 2008). EV71 CNS involvement may be associated with neurological sequelae, delayed neurodevelopment and reduced cognitive functioning. Since poliovirus was nearly eradicated by vaccination, EV71 is now considered as one of the top candidates for new vaccine development against human enteroviruses. Recently, several EV71 vaccine candidates, including live-attenuated virus, inactivated whole virus, recombinant viral protein, virus-like particle and DNA vaccines, have been evaluated in animals but no clinical trial has yet been conducted. Based on historical experiences with poliovirus vaccines and animal studies, the inactivated whole-virus vaccines are feasible and could be licensed readily, so these are targeted for preparing clinical trials in several organizations in Asia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|